UPM Pharmaceuticals, a contract development and manufacturing organization focused on solid oral and semi-solid dosage forms, has appointed Chris Curtin as chief operating officer.

Curtin was promoted from his previous role as executive vice president of quality operations. Curtin will lead the organization responsible for research & development, manufacturing, quality assurance, inventory management, quality control, and analytical services.

Curtin has held executive management positions at: Parke-Davis/Warner Lambert, a Pfizer subsidiary; King Pharmaceuticals, a Pfizer subsdiary; Graceway Pharmaceuticals, a Bristol, Tennessee-headquartered pharmaceutical company; Rockward Pharmaceutical Consultants, a Bristol, Tennessee-based pharmaceutical consulting service; Actient Pharmaceuticals, a subsidiary of Endo International, a  specialty pharmaceutical and generic-drug company; and more recently, Lynwood Pharmaceuticals, a Bristol, Tennessee-based specialty pharmaceutical company.

He has overseen the design, construction, and validation of multiple pharmaceutical facilities and utility systems covering all dosage forms both in and outside of the US.

At King Pharmaceuticals, Curtin was executive vice president, quality operations and responsible for the quality operations of five US-based manufacturing sites covering all dosage forms. At Graceway Pharmaceuticals as executive vice president, technical operations, he was responsible for all quality, supply chain, manufacturing, and engineering operations for US, Canada, and Mexico. This included oversight of seven contract manufacturing organizations producing sterile, solid, and semi-solid dosage forms at US and out-of-US sites.

Source: UPM Pharmaceuticals